Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Guidelines to Practice: Mainstreaming Germline Testing in Prostate Cancer.

JCO oncology practice·2026
Same author

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.

Research square·2026
Same author

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026
Same author

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004-2022).

Cancers·2026

Related Experiment Video

Updated: Jun 4, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.

Rana R McKay1, Shayan S Nazari2, Andrew Elliott2

  • 1University of California San Diego , Moores Cancer Center, San Diego, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 12, 2026
PubMed
Summary

This study reveals KLK2 gene expression varies by prostate cancer type and location. High KLK2 expression correlates with better survival, informing KLK2-targeted therapies.

More Related Videos

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

14.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Related Experiment Videos

Last Updated: Jun 4, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

14.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • KLK2 is an androgen-regulated gene vital in prostate cancer.
  • Emerging therapies target KLK2, necessitating understanding of its expression patterns.

Purpose of the Study:

  • Investigate KLK2 RNA expression patterns in prostate cancer.
  • Correlate KLK2 expression with molecular features and clinical outcomes.

Main Methods:

  • Analyzed DNA/RNA next-generation sequencing data from 7,078 prostate cancer specimens.
  • Defined KLK2-high/low expression using transcripts per million (TPM).
  • Evaluated expression across histology, disease states, and metastatic sites; performed correlative analyses.

Main Results:

  • KLK2 expression varied significantly by histology, highest in adenocarcinoma, lowest in neuroendocrine prostate cancer.
  • Higher KLK2 expression observed in androgen deprivation therapy (ADT)/androgen receptor pathway inhibitor (ARPI)-sensitive vs. exposed tumors.
  • High KLK2 expression associated with improved overall survival (93.9 vs. 74.4 months).
  • KLK2 expression correlated positively with androgen receptor signaling and negatively with neuroendocrine signaling.

Conclusions:

  • Distinct KLK2 expression patterns identified across prostate cancer subtypes and clinical states.
  • Findings provide a molecular framework for understanding KLK2 as a therapeutic target.
  • KLK2 expression patterns offer context for developing KLK2-targeted therapies.